Matt Cooper | Business Development and Marketing Director
NIHR Clinical Research Network

Appearances:

WBC day 1 @ 14:40

Leveraging the NHS to facilitate studies that will generate real-world evidence and help understand the variability in patient uptake

• Evaluating the uptake and use of biosimilars in patients across both ordinary diseases and oncology
• Capturing patient experiences of both being prescribed from first time biosimilars and also switching activities
• Clinician driven or patient driven – How can we justify the variability in patient uptake?